| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Rat |
| Immunogen | Purified recombinant fragment of human CCL15 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与CCL15抗体相关的模拟参考文献(基于研究领域常见方向概括，非真实文献)：
1. **《CCL15 promotes colorectal cancer progression via CCR1-mediated EMT and predicts patient prognosis》**
- 作者：Zhang Y et al.
- 摘要：研究通过开发抗CCL15中和抗体，证明其可阻断CCL15/CCR1信号通路，抑制结直肠癌细胞上皮-间质转化(EMT)和转移，提示其治疗潜力。
2. **《Anti-CCL15 antibody attenuates liver fibrosis by modulating macrophage infiltration》**
- 作者：Tanaka K et al.
- 摘要：在小鼠肝纤维化模型中，抗CCL15抗体通过减少促炎性巨噬细胞向肝脏的募集，显著减轻纤维化程度，为靶向CCL15的肝病治疗提供依据。
3. **《CCL15 as a biomarker in rheumatoid arthritis: Detection and functional analysis using monoclonal antibodies》**
- 作者：Wang L et al.
- 摘要：研究报道了一种高特异性抗CCL15单克隆抗体的开发，用于检测类风湿性关节炎患者滑液中的CCL15水平，并验证其与疾病活动度的相关性。
4. **《Targeting CCL15 in triple-negative breast cancer with a humanized antibody-drug conjugate》**
- 作者：Chen H et al.
- 摘要：构建靶向CCL15的人源化抗体-药物偶联物(ADC)，在临床前实验中显示对三阴性乳腺癌的肿瘤生长抑制和化疗增敏作用。
(注：以上文献为示例性概括，实际文献需通过PubMed/Google Scholar等平台检索。)
CCL15 (C-C motif chemokine ligand 15), also known as leukotactin-1 or HCC-2. is a member of the CC chemokine family characterized by its role in immune regulation and inflammatory responses. It is produced by various cell types, including leukocytes, endothelial cells, and epithelial cells, and signals through chemokine receptors CCR1. CCR3. and CCR5. CCL15 is involved in recruiting immune cells such as monocytes, lymphocytes, and eosinophils to sites of inflammation or injury. Its expression is upregulated in pathological conditions like chronic inflammation, autoimmune diseases, and cancers, where it contributes to disease progression by promoting leukocyte infiltration, angiogenesis, and tumor microenvironment modulation.
CCL15 antibodies are tools designed to detect, quantify, or neutralize CCL15 activity in experimental and therapeutic contexts. These antibodies are typically monoclonal or polyclonal, developed for applications including immunohistochemistry, ELISA, flow cytometry, and functional assays. In research, they help elucidate CCL15's role in disease mechanisms, such as its involvement in tumor metastasis or inflammatory disorders. Therapeutically, neutralizing CCL15 antibodies are explored for their potential to inhibit chemokine-receptor interactions, thereby suppressing inflammation or cancer progression. Recent studies highlight their promise in preclinical models, particularly in targeting CCL15-driven pathways in hepatocellular carcinoma and rheumatoid arthritis, underscoring their relevance in both basic science and drug development.
×
